<SEC-DOCUMENT>0001178913-23-000010.txt : 20230103
<SEC-HEADER>0001178913-23-000010.hdr.sgml : 20230103
<ACCEPTANCE-DATETIME>20230103070527
ACCESSION NUMBER:		0001178913-23-000010
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230103
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230103
DATE AS OF CHANGE:		20230103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813676773
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38807
		FILM NUMBER:		23500176

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>zk2328943.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:cmmb="http://chemomab.com/20230103" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 22.12.1.5105
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_c4648d413a80429490b83737684960a3" contextRef="c20230103to20230103" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_827b499388894d2983d2699b4fac3458" contextRef="c20230103to20230103">00-0000000</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_bb5eac91d82c47d694f161e9a8eda0ed" contextRef="c20230103to20230103">0001534248</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_7800ee96276548b596341b580ba682e4" contextRef="c20230103to20230103_StatementClassOfStockAxis_OrdinarySharesNoParValuePerShareMember">NASDAQ</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_6d5d9dde38ce41a79ef18960f5e679b6" contextRef="c20230103to20230103_StatementClassOfStockAxis_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember">NASDAQ</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="cmmb-20230103.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20230103to20230103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230103to20230103_StatementClassOfStockAxis_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230103to20230103_StatementClassOfStockAxis_OrdinarySharesNoParValuePerShareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:OrdinarySharesNoParValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> </span></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
    <div> <div><br /></div>

      <p style="font: 14pt 'Times New Roman',Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>WASHINGTON, D.C. 20549</b></p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;&#160;</p>
      <p style="font: 14pt 'Times New Roman',Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_1e8d67a5e319479a96041d8c4f7e3915" contextRef="c20230103to20230103">8-K</ix:nonNumeric></b></p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>CURRENT REPORT</b></p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Pursuant to Section&#160;13 or 15(d)</b></p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>of the Securities Exchange Act of 1934</b></p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_097c3bd6996d46e2bd4575c8433d9ffd" contextRef="c20230103to20230103" format="ixt:date-monthname-day-year-en">January 3, 2023</ix:nonNumeric></b></p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
      <p style="font: 16pt 'Times New Roman',Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_54f7699f403b4b8da0f3061dbb621ab8" contextRef="c20230103to20230103">Chemomab Therapeutics Ltd.</ix:nonNumeric><br />
        </b></p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>(Exact name of Registrant as Specified in Its Charter)</b></p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px;">&#160;</p>
      <table cellspacing="0" cellpadding="0" border="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;">


  <tr style="vertical-align: top;">

    <td style="width: 33%; text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">State of <ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_ed7f83e55f0a4b08beddae26671ea988" contextRef="c20230103to20230103" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric></td>

    <td style="width: 33%; text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_23f534d54203453daaea000a94b759db" contextRef="c20230103to20230103">001-38807</ix:nonNumeric><br />
            </td>

    <td style="width: 33%; text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"><span style="-sec-ix-hidden:Fact_827b499388894d2983d2699b4fac3458">81-3676773</span><br />
            </td>

  </tr>

  <tr style="vertical-align: top;">

    <td style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 33%;"><b>(State or Other Jurisdiction</b></td>

    <td style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 33%;"><b>(Commission</b></td>

    <td style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 33%;"><b>(IRS Employer</b></td>

  </tr>

  <tr style="vertical-align: top;">

    <td style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 33%;"><b>of Incorporation)</b></td>

    <td style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 33%;"><b>File Number)</b></td>

    <td style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 33%;"><b>Identification No.)</b></td>

  </tr>


</table>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px;">&#160;</p>
      <table cellspacing="0" cellpadding="0" border="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;">


  <tr>

    <td style="width: 50%; text-align: center; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_e24b9d3f80794d4685c212a8f19bc425" contextRef="c20230103to20230103">Kiryat Atidim, Building 7</ix:nonNumeric></span><br />
            </td>

    <td style="width: 50%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="text-align: center; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 50%;"><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_4fa2b9620e824a57b1f54dd90922a682" contextRef="c20230103to20230103">Tel Aviv</ix:nonNumeric>,
                <ix:nonNumeric name="dei:EntityAddressCountry" id="Fact_b9d79dd8c8ac402da729318d023d8bec" contextRef="c20230103to20230103" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></b></td>

    <td style="text-align: center; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 50%;"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_7d3c117f227b4ad7b829a6bd78c06980" contextRef="c20230103to20230103">6158002</ix:nonNumeric><br />
              </b></td>

  </tr>

  <tr>

    <td style="text-align: center; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 50%;"><b>(Address of principal executive offices)</b></td>

    <td style="text-align: center; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 50%;"><b>(Zip Code)</b></td>

  </tr>


</table>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px;">&#160;</p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px; text-align: center;"><b>Registrant&#8217;s telephone number, including area code: +<ix:nonNumeric name="dei:CityAreaCode" id="Fact_056db533a90749b29f8b400205334538" contextRef="c20230103to20230103">972</ix:nonNumeric>-<ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_a465d30b3ba54a55af9eec32f997a7b4" contextRef="c20230103to20230103">77-331-0156</ix:nonNumeric></b></p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px;">&#160;</p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px; text-align: center;"><b>(Former name or former address, if changed since last report)</b></p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px;">&#160;</p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px;">&#160;</p>
      <table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;">


  <tr style="vertical-align: top;">

    <td style="width: 5%; text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_58591e2e1f2443529562a6b7d3838234" contextRef="c20230103to20230103" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: 95%; text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</td>

  </tr>

  <tr style="vertical-align: top;">

    <td style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

    <td style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

  </tr>

  <tr style="vertical-align: top;">

    <td style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_34813f63dc0844ef81c013044741f24c" contextRef="c20230103to20230103" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</td>

  </tr>

  <tr style="vertical-align: top;">

    <td style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

    <td style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

  </tr>

  <tr style="vertical-align: top;">

    <td style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_c93b00f1407c48d2abcfa1faa8eb2967" contextRef="c20230103to20230103" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</td>

  </tr>

  <tr style="vertical-align: top;">

    <td style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

    <td style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</td>

  </tr>

  <tr style="vertical-align: top;">

    <td style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_ee53ffb1d4404dd9bf8384d2237b75eb" contextRef="c20230103to20230103" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</td>

  </tr>


</table>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px; text-align: center;">&#160;</p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px; text-align: center;"><b>Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px;">&#160;</p>
      <table cellspacing="0" cellpadding="0" border="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;">


  <tr style="vertical-align: bottom;">

    <td style="width: 49%; text-align: center; white-space: nowrap; font-family: 'Times New Roman',Times,serif; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);"><b>Title of each class</b></td>

    <td style="width: 1%; text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; padding-bottom: 2px;">&#160;</td>

    <td style="width: 24%; text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);"><b>Trading<br />
                Symbol(s)</b></td>

    <td style="width: 1%; text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; padding-bottom: 2px;">&#160;</td>

    <td style="width: 25%; text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);"><b>Name of each <br />
                exchange<br />
                on&#160;which&#160;registered</b></td>

  </tr>

  <tr>

    <td style="text-align: center; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 49%; font-weight: bold;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_b123c56576e3485d98bde4754511ff63" contextRef="c20230103to20230103_StatementClassOfStockAxis_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember">American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share</ix:nonNumeric><br />
            </td>

    <td style="text-align: center; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 1%; font-weight: bold;">&#160;</td>

    <td style="text-align: center; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 24%; font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_efc8b1a62843452ea835025b22e31abb" contextRef="c20230103to20230103_StatementClassOfStockAxis_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember">CMMB</ix:nonNumeric><br />
            </td>

    <td style="text-align: center; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 1%; font-weight: bold;">&#160;</td>

    <td style="text-align: center; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 25%; font-weight: bold;"><span style="-sec-ix-hidden:Fact_6d5d9dde38ce41a79ef18960f5e679b6">Nasdaq Capital Market</span><br />
            </td>

  </tr>

  <tr>

    <td style="text-align: center; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 49%; font-weight: bold;">&#160;</td>

    <td style="text-align: center; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 1%; font-weight: bold;">&#160;</td>

    <td style="text-align: center; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 24%; font-weight: bold;">&#160;</td>

    <td style="text-align: center; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 1%; font-weight: bold;">&#160;</td>

    <td style="text-align: center; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 25%; font-weight: bold;">&#160;</td>

  </tr>

  <tr>

    <td style="text-align: center; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 49%; font-weight: bold;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_adcba5d2ba7c41fa96ede1c9ee9b9160" contextRef="c20230103to20230103_StatementClassOfStockAxis_OrdinarySharesNoParValuePerShareMember">Ordinary shares, no par value per share</ix:nonNumeric><br />
            </td>

    <td style="text-align: center; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 1%; font-weight: bold;">&#160;</td>

    <td style="text-align: center; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 24%; font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_e57ed6f5b2144c9b95a26c319b8d02b2" contextRef="c20230103to20230103_StatementClassOfStockAxis_OrdinarySharesNoParValuePerShareMember">N/A</ix:nonNumeric></td>

    <td style="text-align: center; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 1%; font-weight: bold;">&#160;</td>

    <td style="text-align: center; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 25%; font-weight: bold;"><span style="-sec-ix-hidden:Fact_7800ee96276548b596341b580ba682e4">Nasdaq Capital Market</span>*</td>

  </tr>


</table>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px;">&#160;</p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px;">* Not for trading; only in connection with the registration of American Depositary Shares.</p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px;">&#160;</p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule&#160;12b-2 of the
        Securities Exchange Act of 1934 (&#167;&#160;240.12b-2 of this chapter).</p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px;">&#160;</p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px;">Emerging growth company&#160; <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_dd30d57e27ef4063b7ff9d2b9c5d7da4" contextRef="c20230103to20230103" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px;">&#160;</p>
      <p style="font: 10pt 'Times New Roman',Times,serif; margin: 0pt 0px;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
        accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160; <ix:nonNumeric name="dei:EntityExTransitionPeriod" id="Fact_4060debb196f400b9b60e23eaa2c782f" contextRef="c20230103to20230103" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></p>
    </div>

    <div> <span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><br />
      </span></div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

    </div>

    <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
      <div style="line-height: 1.25">
        <div style="line-height: 1.25;"><br />
        </div>

        <div style="line-height: 1.25;">
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 6.61%; vertical-align: top;">
                  <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 8.01</div>
                </td>

    <td style="width: 93.39%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Other Events.</div>
                </td>

  </tr>


</table>
        </div>
<div>
        &#160;<br /></div>

      </div>

      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On January 3, 2023, Chemomab Therapeutics Ltd. issued a press release announcing the top-line results from its
            CM-101 Phase 2a liver fibrosis biomarker trial in NASH patients.</div>

          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</div>

          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 6.61%; vertical-align: top;">
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9.01</div>
              </td>

    <td style="width: 93.39%; vertical-align: top;">
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Financial Statements and Exhibits.</div>
              </td>

  </tr>


</table>
        <div style="line-height: 1.25;">
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d) Exhibits</div>

        </div>

        <div style="line-height: 1.25;">
          <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 8.57%; vertical-align: top; border-bottom: #000000 2px solid;">
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit Number</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;">
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 90.83%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div>
              </td>

  </tr>

  <tr>

    <td style="width: 8.57%; vertical-align: top;">
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit_99-1.htm">99.1</a></div>
              </td>

    <td style="width: 0.6%; vertical-align: top;"> <br />
              </td>

    <td style="width: 90.83%; vertical-align: top;">
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit_99-1.htm">Press release dated
                    January 3, 2023</a></div>
              </td>

  </tr>

  <tr>

    <td style="width: 8.57%; vertical-align: top;">
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;">
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 90.83%; vertical-align: top;">
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
              </td>

  </tr>


</table>
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25;"><br />
          </div>

        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        </div>

        <div style="line-height: 1.25;">
<div>&#160;<br /></div>

          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

          <div style="line-height: 1.25">&#160;</div>

        </div>

      </div>

      <div style="line-height: 1.25;">
        <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
          behalf by the undersigned hereunto duly authorized.</div>

        <div style="line-height: 1.25">&#160;</div>

      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="vertical-align: bottom;" colspan="2">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
            </td>

    <td style="width: 20%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: middle;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 3%; vertical-align: middle;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 27%; vertical-align: middle;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 20%; vertical-align: middle;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Date:&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">January 3, 2023</span></div>
              </div>
            </td>

    <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">By:</div>
            </td>

    <td style="width: 27%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">/s/&#160;</span>Donald Marvin</div>
            </td>

    <td style="width: 20%; vertical-align: middle;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 3%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 27%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name: Donald Marvin</div>
            </td>

    <td style="width: 20%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 3%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 27%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title: Executive V.P., Chief Financial Officer </div>
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">and Chief Operating Officer</div>
            </td>

    <td style="width: 20%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

  </tr>


</table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br />
        </div>

      </div>

    </div>

    <div>
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

  </div>

  <div><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> </span></div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 22.12.1.5105
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"> <u><font style="font-weight: bold;">Exhibit 99.1</font></u><br>
    </div>
    <div>
      <div class="BRPFPageHeader">
        <div style="text-align: left; line-height: 1.25;"><img width="259" height="73" src="image00001.jpg"></div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis </div>
      <div style="text-align: center; margin-right: 33.8pt; margin-left: 33.95pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Biomarker Trial in NASH Patients</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; margin-right: 33.8pt; margin-left: 33.95pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">&#8212;CM-101 Met Primary Endpoint of Safety and Tolerability and Showed
        Positive Activity </div>
      <div style="text-align: center; margin-right: 33.8pt; margin-left: 33.95pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Across Multiple Liver Fibrosis Biomarkers and Physiologic Assessments&#8212;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">TEL AVIV, Israel, January
          3, 2023 </font>-- Chemomab Therapeutics, Ltd. (<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Nasdaq: CMMB) (Chemomab), </font>a clinical-stage biotechnology company focused on the discovery and development
        of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today reported top-line results from its Phase 2a trial assessing CM-101, its first-in-class CCL24-neutralizing monoclonal antibody, in non-alcoholic
        steatohepatitis (NASH) patients. The trial met its primary endpoint of safety and tolerability, and CM-101 achieved reductions in secondary endpoints that include a range of liver fibrosis biomarkers and physiologic assessments measured at baseline
        and at week 20.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The randomized, placebo-controlled trial enrolled 23 NASH patients with stage F1c, F2 and F3 disease who were randomized to
        receive either CM-101 or placebo. Patients received eight doses of 5 mg/kg of CM-101 or placebo, administered by subcutaneous (SC) injection once every two weeks, for a treatment period of 16 weeks. This trial was primarily designed to assess the
        subcutaneous formulation of CM-101 and to evaluate the drug&#8217;s impact on liver fibrosis biomarkers relevant to both NASH and the rare fibro- inflammatory conditions that represent the focus for the company, such as primary sclerosing cholangitis
        (PSC) and systemic sclerosis (SSc).</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Dale Pfost, PhD, Chief Executive Officer of Chemomab, said, &#8220;It is noteworthy that this trial confirmed the safety and
        tolerability of CM-101 and the pharmacokinetics of our subcutaneous formulation, while providing biomarker data further demonstrating the anti-inflammatory and anti-fibrotic activity of CM-101. We are especially pleased with these encouraging
        findings given the small size of the study, the short duration of treatment and the relatively low dose of CM-101 that was administered.<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">&#8221;</font></div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Dr. Pfost continued, &#8220;This is the third clinical trial in patients demonstrating the activity of CM-101 as measured by
        fibro-inflammatory biomarkers and physiological assessments. It confirms similar data we reported in our <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Phase 1b study</u>&#160;</font>in patients with non-alcoholic fatty liver disease (NAFLD) and in our recently reported investigator study of <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>acute lung injury in COVID patients</u>.</font> Collectively, these data encompassing diverse organs and conditions reinforce
        our optimism about our ongoing Phase 2 trial in primary sclerosing cholangitis and our Phase 2 trial in systemic sclerosis that is scheduled to begin early this year.&#8221;</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Key findings of the CM-101 Phase 2a trial included the following.</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z588085f31f6f4b318a7c85bae8dd4499" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9726;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">CM-101 continues to appear safe and was well tolerated when
                  administered subcutaneously</font>. Most reported adverse events observed were mild, with one unrelated serious adverse event reported. No significant injection site reactions were observed and no anti-drug antibodies were detected.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="ze98f806ba59b4e249125b6a4c3c3eb4e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9726;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">CM-101 administered subcutaneously demonstrated favorable
                  pharmacokinetics and target engagement profiles </font>as expected; they were similar to what the company has previously reported.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="ze715504fc99e4dad9470ad9111d8ae01" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9726;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">CM-101-treated patients showed greater improvements than the placebo
                  group in a number of liver fibrosis-related biomarkers</font>, including ProC-3, ProC-4, ProC-18, TIMP-1 and ELF.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z53b0c8d9bdf84731bd8b74ad0d7f51e9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9726;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">A majority of CM-101-treated patients showed improvements in more than
                  one liver fibrosis- related biomarker&#8212;almost 60% of CM-101-treated patients responded in at least three biomarkers </font>at week 20, compared to no patients in the placebo group.</div>
            </td>
          </tr>

      </table>
      <div class="BRPFPageHeader">
        <div style="text-align: left; line-height: 1.25;"><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" id="zfe2661d467e7483387251d6507aeb552" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9726;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">CM-101-treated patients with higher CCL24 levels at baseline showed
                  greater reductions in fibrosis-related biomarkers than patients with lower CCL24 levels</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</font> Patients with higher CCL24 at baseline were also more
                likely to be responders in multiple fibrosis-related biomarkers than patients with lower CCL24 levels, adding to the growing body of evidence validating the role of CCL24 in the pathophysiology of fibrotic liver disease.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z9977b12628324dd89f6e8f9405462133" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9726;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">A higher proportion of patients in the CM-101-treated group showed
                  improvement in a physiologic measure of liver stiffness </font>as compared to placebo (reduction of at least one grade of fibrosis score as assessed by the non-invasive elastography method known as FibroScan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#174;</font></sup>).</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="zd72f8e4e9a334cdaa0d19372c1eab7ea" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9726;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">After completion of the study, the unblinded data showed that patients in the CM-101-treated group had higher baseline levels of fibrosis compared to placebo-treated
                patients. The impact of this difference on the results, if any, is unknown.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Massimo Pinzani, MD, PhD, Professor of Medicine, Director of the University College London (UCL) Institute for Liver and
        Digestive Health and the Sheila Sherlock Chair of Hepatology at UCL, commented, &#8220;These encouraging Phase 2a results for CM-101 are a good example of what one is seeking in a successful biomarker study&#8211;sets of multiple biomarkers moving together in
        a positive direction. Based on these early findings, CM-101 may have the potential to interrupt the inflammatory and fibrotic vicious cycle characterizing conditions such as PSC, systemic sclerosis and other fibro-inflammatory diseases, providing
        the potential for much-needed disease-modifying therapy.&#8221;</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Rifaat Safadi, MD, Professor in Medicine, Gastroenterology and Hepatology, Faculty of Medicine, Hadassah University Hospital,
        Jerusalem; a Visiting Scholar at the Division of Liver Diseases, Mount Sinai School of Medicine in New York City, and Principal Investigator of the Phase 2a study noted, &#8220;The results from this early trial confirm previous clinical and preclinical
        research suggesting that neutralizing the pro-fibrotic and pro-inflammatory effects of CCL24 may have a therapeutic benefit for patients battling intractable fibro-inflammatory diseases such as PSC and systemic sclerosis, and support the conduct of
        additional clinical trials to address this unmet medical need. I want to thank the patients who participated in this trial and the team members at the clinical sites who helped make these encouraging results possible.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">For more information on Chemomab&#8217;s Phase 2 SPRING trial In patients with primary sclerosing cholangitis, visit <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>www.chemomab.com/trials/psc/</u>,</font> or <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>click here</u>&#160;</font>for information for potential participants.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">About Chemomab Therapeutics</div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Chemomab is a clinical stage biotechnology company focusing on the discovery and development of innovative therapeutics for
        fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24
        activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. A Phase 2 liver fibrosis biomarker study in NASH patients was recently completed and a Phase 2 trial in primary
        sclerosing cholangitis patients is ongoing. Chemomab expects to begin enrolling patients in a Phase 2 trial in systemic sclerosis early in 2023. For more information on Chemomab, visit <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>chemomab.com</u>.</font></div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Forward Looking Statements</div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act.
        These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101 and the results of the Phase 2a Liver Fibrosis Biomarker trial in NASH patients on future development plans; the future
        operations of Chemomab and its ability to successfully initiate and complete clinical trials and achieve regulatory milestones; the nature, strategy and focus of Chemomab; the development and commercial potential and potential benefits of any
        product candidates of Chemomab; and that the product candidates have the potential to address high unmet needs of patients with serious fibrosis-related diseases and conditions. Any statements contained in this communication that are not statements
        of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Chemomab&#8217;s current expectations.</div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Forward-looking statements involve risks and uncertainties. Because such statements deal with future events and are based on
        Chemomab&#8217;s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Chemomab could differ materially from those described in or implied by the statements in this presentation,
        including: risks related to Chemomab&#8217;s ability to effectively implement the revised clinical strategy and its ability to achieve the anticipated results; risks related to the projections and associated benefits in pursuing the contemplated changes
        to the clinical strategy; risks associated with the ongoing transitions of certain of our executive officers, including Chemomab&#8217;s new Chief Executive Officer; the uncertain and time-consuming regulatory approval process; risks related to
        Chemomab&#8217;s ability to correctly manage its operating expenses and its expenses; Chemomab&#8217;s plans to develop and commercialize its product candidates, focusing on CM- 101; the timing of initiation of Chemomab&#8217;s planned clinical trials; the timing of
        the availability of data from Chemomab&#8217;s clinical trials including any potential delays associated with Chemomab&#8217;s contemplated revised clinical strategy; the timing of any planned investigational new drug application or new drug application;
        Chemomab&#8217;s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Chemomab&#8217;s product candidates; Chemomab&#8217;s commercialization, marketing and
        manufacturing capabilities and strategy; Chemomab&#8217;s ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or
        at all.</div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Additional risks and uncertainties relating to Chemomab&#8217;s and its business can be found under the caption &#8220;Risk Factors&#8221; and
        elsewhere in Chemomab&#8217;s filings and reports with the SEC. Chemomab expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Chemomab&#8217;s
        expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except to the extent required by applicable law.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Contacts:</div>
      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z9590abeae5c5470ab95e82b28976208d" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Media:</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Investor Relations:</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Barbara Lindheim</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Irina Koffler</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Chemomab Therapeutics</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">LifeSci Advisors, LLC</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Consulting Vice President</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Phone: +1-917-734-7387</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left; margin-right: 134.1pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investor &amp; Public Relations,</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left; margin-right: 134.1pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>ir@chemomab.com</u>&#160;</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" rowspan="1">Strategic Communications</td>
            <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Phone: +1-917-355-9234</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><u>barbara@chemomab.com</u></div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div> <br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cmmb-20230103.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.12.1.5105 Broadridge-->
<xs:schema targetNamespace="http://chemomab.com/20230103" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:cmmb="http://chemomab.com/20230103" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20230103_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20230103_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20230103_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://chemomab.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xs:element name="AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember" id="cmmb_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OrdinarySharesNoParValuePerShareMember" id="cmmb_OrdinarySharesNoParValuePerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>cmmb-20230103_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.12.1.5105 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://chemomab.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="cmmb-20230103.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://chemomab.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentType" xlink:title="definition: EntityListingsLineItems to DocumentType" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="AmendmentFlag" xlink:title="definition: EntityListingsLineItems to AmendmentFlag" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="definition: EntityListingsLineItems to DocumentPeriodEndDate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityRegistrantName" xlink:title="definition: EntityListingsLineItems to EntityRegistrantName" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityIncorporationStateCountryCode" xlink:title="definition: EntityListingsLineItems to EntityIncorporationStateCountryCode" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityFileNumber" xlink:title="definition: EntityListingsLineItems to EntityFileNumber" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityTaxIdentificationNumber" xlink:title="definition: EntityListingsLineItems to EntityTaxIdentificationNumber" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine1" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine2" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine2" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine3" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine3" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCityOrTown" xlink:title="definition: EntityListingsLineItems to EntityAddressCityOrTown" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressStateOrProvince" xlink:title="definition: EntityListingsLineItems to EntityAddressStateOrProvince" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCountry" xlink:title="definition: EntityListingsLineItems to EntityAddressCountry" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressPostalZipCode" xlink:title="definition: EntityListingsLineItems to EntityAddressPostalZipCode" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="CityAreaCode" xlink:title="definition: EntityListingsLineItems to CityAreaCode" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="LocalPhoneNumber" xlink:title="definition: EntityListingsLineItems to LocalPhoneNumber" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="WrittenCommunications" xlink:title="definition: EntityListingsLineItems to WrittenCommunications" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="SolicitingMaterial" xlink:title="definition: EntityListingsLineItems to SolicitingMaterial" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementTenderOffer" xlink:title="definition: EntityListingsLineItems to PreCommencementTenderOffer" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="definition: EntityListingsLineItems to PreCommencementIssuerTenderOffer" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="NoTradingSymbolFlag" xlink:title="definition: EntityListingsLineItems to NoTradingSymbolFlag" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityEmergingGrowthCompany" xlink:title="definition: EntityListingsLineItems to EntityEmergingGrowthCompany" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="EntityExTransitionPeriod" xlink:title="EntityExTransitionPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityExTransitionPeriod" xlink:title="definition: EntityListingsLineItems to EntityExTransitionPeriod" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="definition: EntityListingsLineItems to DocumentFiscalYearFocus" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="definition: EntityListingsLineItems to DocumentFiscalPeriodFocus" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityCentralIndexKey" xlink:title="definition: EntityListingsLineItems to EntityCentralIndexKey" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="Security12bTitle" xlink:title="definition: EntityListingsLineItems to Security12bTitle" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="TradingSymbol" xlink:title="definition: EntityListingsLineItems to TradingSymbol" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="SecurityExchangeName" xlink:title="definition: EntityListingsLineItems to SecurityExchangeName" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EntityListingsLineItems" xlink:to="EntityListingsTable" xlink:title="definition: EntityListingsLineItems to EntityListingsTable" order="30.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="EntityListingsTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: EntityListingsTable to StatementClassOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="cmmb-20230103.xsd#cmmb_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember" xlink:label="AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember" xlink:title="AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember" xlink:title="definition: ClassOfStockDomain to AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="cmmb-20230103.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="OrdinarySharesNoParValuePerShareMember" xlink:title="OrdinarySharesNoParValuePerShareMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="OrdinarySharesNoParValuePerShareMember" xlink:title="definition: ClassOfStockDomain to OrdinarySharesNoParValuePerShareMember" order="2.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>cmmb-20230103_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.12.1.5105 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockDomain_lbl">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xlink:title="label: ClassOfStockDomain to us-gaap_ClassOfStockDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="us-gaap_StatementClassOfStockAxis_lbl">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:title="label: StatementClassOfStockAxis to us-gaap_StatementClassOfStockAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="EntityExTransitionPeriod" xlink:title="EntityExTransitionPeriod" />
    <link:label xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" id="dei_EntityExTransitionPeriod_lbl">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:title="label: EntityExTransitionPeriod to dei_EntityExTransitionPeriod_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:label xlink:type="resource" xlink:label="dei_EntityListingsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityListingsTable_lbl" xml:lang="en-US" id="dei_EntityListingsTable_lbl">Entity Listings [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityListingsTable" xlink:to="dei_EntityListingsTable_lbl" xlink:title="label: EntityListingsTable to dei_EntityListingsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:label xlink:type="resource" xlink:label="dei_EntityListingsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityListingsLineItems_lbl" xml:lang="en-US" id="dei_EntityListingsLineItems_lbl">Entity Listings [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityListingsLineItems" xlink:to="dei_EntityListingsLineItems_lbl" xlink:title="label: EntityListingsLineItems to dei_EntityListingsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
    <link:loc xlink:type="locator" xlink:href="cmmb-20230103.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="OrdinarySharesNoParValuePerShareMember" xlink:title="OrdinarySharesNoParValuePerShareMember" />
    <link:label xlink:type="resource" xlink:label="cmmb_OrdinarySharesNoParValuePerShareMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cmmb_OrdinarySharesNoParValuePerShareMember_lbl1" xml:lang="en-US" id="cmmb_OrdinarySharesNoParValuePerShareMember_lbl1">Ordinary shares, no par value per share [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrdinarySharesNoParValuePerShareMember" xlink:to="cmmb_OrdinarySharesNoParValuePerShareMember_lbl1" xlink:title="label: OrdinarySharesNoParValuePerShareMember to cmmb_OrdinarySharesNoParValuePerShareMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="cmmb-20230103.xsd#cmmb_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember" xlink:label="AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember" xlink:title="AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember" />
    <link:label xlink:type="resource" xlink:label="cmmb_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cmmb_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember_lbl1" xml:lang="en-US" id="cmmb_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember_lbl1">American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember" xlink:to="cmmb_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember_lbl1" xlink:title="label: AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember to cmmb_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember_lbl1" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>cmmb-20230103_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.12.1.5105 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://chemomab.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="cmmb-20230103.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://chemomab.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="cmmb-20230103.xsd#cmmb_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember" xlink:label="AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember" xlink:title="AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember" xlink:title="presentation: ClassOfStockDomain to AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="cmmb-20230103.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="OrdinarySharesNoParValuePerShareMember" xlink:title="OrdinarySharesNoParValuePerShareMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="OrdinarySharesNoParValuePerShareMember" xlink:title="presentation: ClassOfStockDomain to OrdinarySharesNoParValuePerShareMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: EntityListingsTable to StatementClassOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentType" xlink:title="presentation: EntityListingsLineItems to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="AmendmentFlag" xlink:title="presentation: EntityListingsLineItems to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: EntityListingsLineItems to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityRegistrantName" xlink:title="presentation: EntityListingsLineItems to EntityRegistrantName" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: EntityListingsLineItems to EntityIncorporationStateCountryCode" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityFileNumber" xlink:title="presentation: EntityListingsLineItems to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: EntityListingsLineItems to EntityTaxIdentificationNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine2" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine3" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: EntityListingsLineItems to EntityAddressCityOrTown" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: EntityListingsLineItems to EntityAddressStateOrProvince" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCountry" xlink:title="presentation: EntityListingsLineItems to EntityAddressCountry" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: EntityListingsLineItems to EntityAddressPostalZipCode" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="CityAreaCode" xlink:title="presentation: EntityListingsLineItems to CityAreaCode" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="LocalPhoneNumber" xlink:title="presentation: EntityListingsLineItems to LocalPhoneNumber" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="WrittenCommunications" xlink:title="presentation: EntityListingsLineItems to WrittenCommunications" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="SolicitingMaterial" xlink:title="presentation: EntityListingsLineItems to SolicitingMaterial" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: EntityListingsLineItems to PreCommencementTenderOffer" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: EntityListingsLineItems to PreCommencementIssuerTenderOffer" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: EntityListingsLineItems to NoTradingSymbolFlag" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: EntityListingsLineItems to EntityEmergingGrowthCompany" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="EntityExTransitionPeriod" xlink:title="EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityExTransitionPeriod" xlink:title="presentation: EntityListingsLineItems to EntityExTransitionPeriod" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: EntityListingsLineItems to DocumentFiscalYearFocus" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: EntityListingsLineItems to DocumentFiscalPeriodFocus" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityCentralIndexKey" xlink:title="presentation: EntityListingsLineItems to EntityCentralIndexKey" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="Security12bTitle" xlink:title="presentation: EntityListingsLineItems to Security12bTitle" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="TradingSymbol" xlink:title="presentation: EntityListingsLineItems to TradingSymbol" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="SecurityExchangeName" xlink:title="presentation: EntityListingsLineItems to SecurityExchangeName" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsTable" xlink:to="EntityListingsLineItems" xlink:title="presentation: EntityListingsTable to EntityListingsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityListingsTable" xlink:title="presentation: CoverAbstract to EntityListingsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "9 AT# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"#_LJN?YM^E>QUMBYN53EZ(BC&T;]PHHHKE-0J&Z_P"/.?\ ZYM_*IJANO\
MCSG_ .N;?RH0'RM\,KNWL/B/8W=W,D-O#YSR2.<!0(VR37:^)/CKJ-Q>O;>&
M+-$@4X6>9"\C^X7H!]<UY3I.ESZWX@MM+MCB:ZG$2GL,GDGV YKZQ\,^#M&\
M*Z=':Z?9Q^8%'F7#(#)(?4G^E>IB73A)2DKLY:2DU9:'@]I\:_&5C= W9MKA
M<Y:*:#9Q]1@BO:O OC[3O&^GO);J;>]A \^U9LE?<'NOO5[Q1X.TCQ7I<MI?
M6L?F%3Y5PJ 21-V(/].]?.7@B[NO"'Q1M;>1BICNS97"@\,"VP_K@_A67+3K
MP;BK-%7E3DKNZ/JRL7Q-XJTKPEIAOM4N-BGB.)>7E/HH[UL22+%$TCD*B LQ
M/8"OEC7-1U+XH_$1+>W<^7-+Y-HA/RQ1 GYC^&2:YZ%'VCN]D:5)\JTW.BU;
MXZ^(;^Y,6B6$%K&3\FY#+(?Z?I5%/B_X]TV17O41DS]VXL]@/XC%>Y^%?!6B
M^$K!(+"U0SX'F7+J#)(?4GT]JW+FTM[V!H+J"*>)AADE0,I'T-:NO13LH:$^
MSF]7(\Z\#_&#3/$]Q'IVHQ#3]1?A 6S%*?0$]#['\S7I=?-WQ<\ 0^$[VWUC
M1U:*PN7VF-3_ *B3J,>@/;TQ]*]?^&/BA_%7@RWN;A]UY;DV]P?[S#HWX@@_
M7-36I0Y54I[,<)N_++<P?B?\2M5\$:Q96>GVEE-'/;^:QN%8D'<1QAAZ5GZM
M\;H].\-:=)%:P7&MW5N)98E)$4&>F><Y]L_C7-_M!?\ (SZ5_P!>1_\ 0S6O
M\&/ %C<:6/$NJVZ7$DCE;2*5<J@4X+8/4YZ>F*V4*4:,9R7_  2'*;FXHY&7
MXR>.1()S-#'&3POV4;/UY_6N]\!_&A-;OXM+U^"&UN92%AN8CB-V[!@?ND^O
M3Z5ZM<6%G=6[6]Q:P2PL-K1O&&4CZ&OE_P"*GA*#PAXM"6 9+*Z3SX%S_JSD
M@J/H>GUHINE7]SELPEST];W/5?'OQBMO#5[)I>D01WNH1\2R.?W41]..6/MQ
MBO-Y?C'XZW>>9HHXCT M1M_,_P"-=5\&? EGJ5G)XHUB%;N225EMDF&Y>#\S
MD'J<\#Z&O:I+.UF@,,MM"\1&"C("I'TJ'.C1?)RW&E.:O>QY'X'^-JZI?PZ;
MXB@BMY96"1W<7"%NP8$\9]1^E>QU\O?%SPC;>%?%2/I\?E65['YL<8Z1L#A@
M/;H?QKWOX>ZO)KG@+2+^=BTS0[)&/4LA*D_CC/XU.(IPY54ALQTY.[C(Z1W2
M.-I)&5$499F. !ZFO(O%GQTL=.N)+3P];+?R(<&YE)$6?]D#EOTJG\<_&<UL
M(O"]C*4,J"6\93R5/W4_'&3^%0?"KX56=WIT/B#Q! )Q-\UM:./EV_WG'?/8
M>E.G2A"'M*OR02G)RY8G+/\ &/QU=/YL,L2)G[L5J"/US6KHWQZURUF5-8L;
M:\ASAFB!CD']/TKZ AL[6WB$4%M#%&!@(B!0/P%<SXK^'F@>*[.1+BSBM[S'
M[N[A0*ZGMG'WA[&FJ]&6DH60O9S6JD:/AGQ9I'BW3OMFE7&\#B2)N)(CZ,.W
M\JVZ^3M-O=6^%WCYHY20]M(([B-3\LT1P?U'(]#7U7:745[9P7=NX>&>-9(V
M'=6&0?R-98BC[-IQV9=.?,M=SQNW^,NKMX\.B7%IIL5BM\]N\Q#AE16(W$EL
M9P/2J?BGXZ7DE\]GX6M4\E3@7,R%FD]U7L/KG\*\NUZWEN_'&IVT"EIIM2EC
M11W)D( KZ>\&^!=*\(:3%!!;127I4>?=,@+NW?![#T%=-6-&DE)J_D90<YW5
MSP^V^-?C.QN0;I[:=<Y,4UOMX_#!KV+PE\3M&\2Z%=7\SK8RV2;[N*5Q\B_W
ME/<?UXK8\4>#](\5Z5+9WUK%YA4^5<*@WQ-V(/\ 3O7R2]I>6FI3Z6"RSF4V
MTB*QPQ#8P?49 HA"EB(Z*S0-SIO5W/6/$/QWU.YO'M_#=E'% #A9IT+R/[A>
M@_6L.#XT^-;*X#7+V\RYR8YK<+D?A@U[;X*\":7X1T>")+:*2_9 ;BY9069L
M<@'LN>@K2\1>%M)\3Z7+8ZA:1/O4A)0HWQMV*GM6?MJ"?*H:%<E1J]S&\ _$
M2P\<6CJL?V;481F:V+9X_O*>X_E79U\F^#[BZ\)?$^QA9BKPWWV.?'=2VQO\
M?PKZRK/$TE3E[NS+I3<EJ<YXS\9:=X+T<WMX=\SY6WMU/S2M_0#N:^>M1\6>
M-?B+JC6EJ;IT8_+9V0*HB_[6.WNQI/&>J7OQ ^)+6MHQ=&G%I9IGY54'&[\3
MEC7T7X2\)Z=X0T6*PL8EWX!FG(^:5^Y)_D.U;)1P\$VKR9GK4=EL>"0_ [QC
M-")'6PB8C.R2X^8?D"/UJG+I_P 0/AG,MR/M=M;J>7C;S8&]FZC\\5]2U'-!
M%<P/!/&DL4BE71UR&![$5"QDW\2317L%T9X#XH^)B>+OAHR;C9ZQ;W,?G1Q.
M5#KS\R]\9ZCM75? 6YGN?"^IM/-)*PO< R.6(&Q?6O-?BOX'C\(:^DUBI&F7
MP+Q+_P \V'WD^G((^OM7HO[/W_(JZI_U^_\ LBUM5C!8>\-F1!R]I:1V'Q._
MY)MKO_7O_P"S"O'_ ((:I9:+J&O:AJ%PD%K#9J7=S_MCCW)]*]@^)W_)-M=_
MZ]__ &85\O\ AW1[[Q%K5MHUB2)+MP#R=H Y+'V R:G#14J,D]@JMJ::/4/$
M/QYU&XN6A\.V,<$.<++<+OD;_@(.!^M8*?&7QQ:2AYY874G[DMJ #^6#7NGA
M;P'H7A.R2*SLXY+G'[RZE0-(Y^O8>PK<O=,L-1MVM[VRM[B%A@I+&&!_.L_;
M48Z*%T7R3>K9YOX)^,^G^(+F/3]8@33[V0A8Y V89#Z9/*GZ_G7J=?-/Q7^'
M4?A&[BU/2@W]EW+[=A.3!)UQGT/./I7J7PB\7OXB\(^3?3;KW3V$+NYY=<?*
MQ]\9'X4JU&')[6GL$)N_++<RO'/AN;3]2DU&",M9SMN8J/\ 5L>H/L:X^OH=
MT25&2159&&"K#((KG;KP)H%U(9/LC1$G)$3E1^5>KA,XC""A66W5$SH7=XGC
M:JSL%4%F)P !R:]3\&^#HK&W6_U* ->/RD;C/E#Z>O\ *M[3/#&CZ2XDM;-!
M*.DCG<P^A/2M>L,=FSK1]G2T7XCIT>5W854OM+L=2B,=Y:Q3*?[R\CZ'J*MT
M5X\9.+NG8W/+?%/@1]-B>^TPM);+R\1Y:,>H]169X,\0+H6K'SR1:7 "2G^[
MCHWX?UKV0@$$$9!Z@UY?XL\#SVLTE]I41EMF.YH5&6C^@[C^5>_@\='$0>'Q
M+WZ_UU.:=-Q?-$ZCQ;X)T7QWI\/VPD2(,P7<##<H/Z$>U<=I'P%T6QOTN-0U
M&XU")#D0&,1JW^\022/RK&TSQ'JVBYCM+IUC!YB<;E'X'I6E/\0-?GBV">*+
M(QNCC /ZYJ7E6*@^6G-<H>TIO5K4](U?Q%I7AV.**X8@D82&%02%'MV%7M-U
M*UU:Q2\M'WQ/ZC!![@^]>)V6G:GXAOR(4EN)G/SRN20/=F->P^'=%70='CLA
M)YCY+NW8L>N/:N;'8.CAJ:7->9=.<I/;0UJ***\HV"BBB@ KRCX^6C3>#;*Y
M49%O>#<?0,I'\\5ZO6'XPT!?$_A34-). \\?[MC_  N#E3^8%:49<E129,U>
M+1YQ^S[?(^A:M8;OWD5RLV/]EEQ_-?UKV.OE#P!XFF\">-0U[&\<#$VU[&1R
M@SUQZJ1G\Z^JX)XKJWCN()%EAE4.CH<A@>A!K;%P<:G-T9%&5XV[$E%%%<IJ
M%0W7_'G/_P!<V_E4Q('4U#=?\><__7-OY4(#Y<^$X!^*6EY&</*1_P!\-7U3
M7RO\)O\ DJ6E_P"]+_Z U?5%=F._B+T,*'PA7RCKO_)9+G_L,C_T8*^KJ^4=
M=_Y+)<_]AD?^C!3P6\O0*^R/HOQ_=/9> -<G0D,+-U!'^T-O]:^8_!7BF7P?
MKW]JPV*7D@B:-4=B N<<\?3'XU]3>+=.;5_"&KV$8S)/:R*@]6QD?KBOGWX+
M:C;V'CX6MXJ;;V!K=1(.CY##KW^4C\:K#-*E/2XJJ?.CH?\ A?\ JO\ T+MO
M_P!_F_PH_P"%_P"J_P#0NV__ '^;_"O=/L=M_P ^T/\ WP*/L=M_S[0_]\"L
MO:T?Y/Q+Y)_S'S;XP^*]]XP\/2:3<:)# KNKB59&8J0?3%=7^SW+*(=>MW#!
M T+KGU.\'^0_*O9C:6H&3;PC_@ J2.&*+/EQHF>NU0,T3Q$73=.,; J;YN9L
M^?OV@O\ D9]*_P"O(_\ H9KUGX:*%^'&A8&,VP/ZFO)OV@O^1GTK_KR/_H9K
MUKX;?\DXT'_KU'\S5U?]W@3#^(SJJ\&_:$_Y"6B?]<9/YBO>:\&_:$_Y"6B?
M]<9/YBL\)_&15;X&>B?"0 ?"_1<#^"7_ -&O7:UQ?PE_Y)?HO^Y)_P"C7KM*
MRK?Q)>K+A\*/"_VAO]=X?_W9_P#V2NZ^#W_),=+^LO\ Z,:N%_:&_P!;X?\
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M7^&- UB'5;"VG2ZA)*,TQ8#((/'T-=E3Q-6-22<14H.*LPKY1UW_ )+)<_\
M89'_ *,%?5U<9<_"WPO=:\VLRVTYO7G^T%A.P&_.>GUHP]6--OFZA4@Y6L=G
M7SE\5? %YX<UN3Q%I$;_ -GS2><S1=;:7.>W1<\@]NGI7T;3719$9'4,C##*
MPR"*BC5=*5T.<%)6/%/"?QVMQ:1VOB:WE$R +]K@7<']V7L?I75S_&KP3%"7
MCOKB9@.(TMG!/Y@#]:?K?P<\(ZQ*TR6LMA*QRQM'V@G_ '2"!^ K$B^ 'AY)
M-TFIZE(H/W<H,_CMK=O#2UU1'[U:'"^,_BAJ_CF:/1M$M9K:TDD 6*,[I9VS
MQG'0=\#\Z]U\&6.LZ=X5L[;7KPW6H*N9&."5'92?XB!WIOASP1X?\*KG2M/2
M.8C#3N=\C?\  CT^@Q70UG6JQDE""LD5"#3O)ZGSW^T%_P C/I7_ %Y'_P!#
M->M?#;_DG&@_]>H_F:?XF\ Z!XNO(;K5X)9)88_+0I*5XSGM]:V])TNUT72K
M;3;)66VMTV1AFR0/K1.K&5*,%N@C!J;D7*\&_:$_Y"6B?]<9/YBO>:YOQ/X&
MT/Q?+;R:O#+(UNI6/9*4P#UZ?2IH5%3J*3'4BY1LC/\ A+_R2_1?]R3_ -&O
M7:50T31K/P_H]OI>GHR6MN"(U9MQ&22>?J35^HJ24IMHJ*LDCPO]H;_6^'_]
MV?\ ]DKNO@]_R3'2_K+_ .C&K8\4>"-$\8-;'5X99#;!A'LD*8W8ST^@K1T+
M0[+PYI$.EZ<C):PYV*S%CR23S]36LJL715/JB%!J;D<A\4_ +>,='2XL57^U
M;,$Q G'FKW3/ZC_Z]>-^"OB%K'P]O)M.N[5YK+S/WUG*=CQMW*YZ'VZ&OJ2N
M>\1^"/#_ (J7.JZ>DDP&%G0E)!_P(=?QJJ5=*/)45T*=-M\T=SF+;XW^#IH
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M1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV/;(-;=<;33LS9.ZN%%%%(84444 %%%% !1110 4444 %%%% !1110 4444
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M8^I(I6TN,M45S6IQ:G;7UHD>KRA+JX*;?+7Y!@GBMZTAE@MECFN&N)!G,C
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1_>LMO^0\/\]JUZ<GH@1__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139785734645968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 03, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  03,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Chemomab Therapeutics Ltd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Kiryat Atidim, Building 7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6158002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">77-331-0156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001534248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmmb_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember', window );">American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CMMB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmmb_OrdinarySharesNoParValuePerShareMember', window );">Ordinary shares, no par value per share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, no par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmmb_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmmb_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmmb_OrdinarySharesNoParValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmmb_OrdinarySharesNoParValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>zk2328943_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cmmb="http://chemomab.com/20230103"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cmmb-20230103.xsd" xlink:type="simple"/>
    <context id="c20230103to20230103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="c20230103to20230103_StatementClassOfStockAxis_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="c20230103to20230103_StatementClassOfStockAxis_OrdinarySharesNoParValuePerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:OrdinarySharesNoParValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20230103to20230103"
      id="Fact_c4648d413a80429490b83737684960a3">false</dei:AmendmentFlag>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20230103to20230103"
      id="Fact_827b499388894d2983d2699b4fac3458">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:EntityCentralIndexKey
      contextRef="c20230103to20230103"
      id="Fact_bb5eac91d82c47d694f161e9a8eda0ed">0001534248</dei:EntityCentralIndexKey>
    <dei:SecurityExchangeName
      contextRef="c20230103to20230103_StatementClassOfStockAxis_OrdinarySharesNoParValuePerShareMember"
      id="Fact_7800ee96276548b596341b580ba682e4">NASDAQ</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="c20230103to20230103_StatementClassOfStockAxis_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember"
      id="Fact_6d5d9dde38ce41a79ef18960f5e679b6">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20230103to20230103"
      id="Fact_1e8d67a5e319479a96041d8c4f7e3915">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20230103to20230103"
      id="Fact_097c3bd6996d46e2bd4575c8433d9ffd">2023-01-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20230103to20230103"
      id="Fact_54f7699f403b4b8da0f3061dbb621ab8">Chemomab Therapeutics Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20230103to20230103"
      id="Fact_ed7f83e55f0a4b08beddae26671ea988">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20230103to20230103"
      id="Fact_23f534d54203453daaea000a94b759db">001-38807</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20230103to20230103"
      id="Fact_e24b9d3f80794d4685c212a8f19bc425">Kiryat Atidim, Building 7</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20230103to20230103"
      id="Fact_4fa2b9620e824a57b1f54dd90922a682">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="c20230103to20230103"
      id="Fact_b9d79dd8c8ac402da729318d023d8bec">IL</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="c20230103to20230103"
      id="Fact_7d3c117f227b4ad7b829a6bd78c06980">6158002</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20230103to20230103"
      id="Fact_056db533a90749b29f8b400205334538">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20230103to20230103"
      id="Fact_a465d30b3ba54a55af9eec32f997a7b4">77-331-0156</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20230103to20230103"
      id="Fact_58591e2e1f2443529562a6b7d3838234">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20230103to20230103"
      id="Fact_34813f63dc0844ef81c013044741f24c">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20230103to20230103"
      id="Fact_c93b00f1407c48d2abcfa1faa8eb2967">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20230103to20230103"
      id="Fact_ee53ffb1d4404dd9bf8384d2237b75eb">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20230103to20230103_StatementClassOfStockAxis_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember"
      id="Fact_b123c56576e3485d98bde4754511ff63">American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20230103to20230103_StatementClassOfStockAxis_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember"
      id="Fact_efc8b1a62843452ea835025b22e31abb">CMMB</dei:TradingSymbol>
    <dei:Security12bTitle
      contextRef="c20230103to20230103_StatementClassOfStockAxis_OrdinarySharesNoParValuePerShareMember"
      id="Fact_adcba5d2ba7c41fa96ede1c9ee9b9160">Ordinary shares, no par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20230103to20230103_StatementClassOfStockAxis_OrdinarySharesNoParValuePerShareMember"
      id="Fact_e57ed6f5b2144c9b95a26c319b8d02b2">N/A</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20230103to20230103"
      id="Fact_dd30d57e27ef4063b7ff9d2b9c5d7da4">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="c20230103to20230103"
      id="Fact_4060debb196f400b9b60e23eaa2c782f">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MC,(RRS: ^RLIS>N)_4!9?%\>_@-02P,$%     @ K3@C5I^@&_"Q @  X@P
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M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ K3@C5@=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" "M."-6V>#15^T    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " "M."-6F5R<(Q &  "<)P  $P
M    @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( *TX(U97
MI9AZ 04  &L6   8              " @0P(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " "M."-6GZ ;\+$"  #B#   #0
M    @ %##0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *TX(U:7BKL<P
M !,"   +              "  1\0  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M *TX(U8<.&7J/P$  #P"   /              "  0@1  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " "M."-6)!Z;HJT   #X 0  &@
M@ %T$@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "M
M."-699!YDAD!  #/ P  $P              @ %9$P  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"  "C%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="zk2328943.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chemomab.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName -  zk2328943.htm 11</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="zk2328943.htm">zk2328943.htm</File>
    <File>cmmb-20230103.xsd</File>
    <File>cmmb-20230103_def.xml</File>
    <File>cmmb-20230103_lab.xml</File>
    <File>cmmb-20230103_pre.xml</File>
    <File>exhibit_99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "zk2328943.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 26
   },
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "cmmb-20230103_def.xml"
     ]
    },
    "inline": {
     "local": [
      "zk2328943.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cmmb-20230103_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cmmb-20230103_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cmmb-20230103.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 36,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 2,
   "memberStandard": 0,
   "nsprefix": "cmmb",
   "nsuri": "http://chemomab.com/20230103",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2328943.htm",
      "contextRef": "c20230103to20230103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://chemomab.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2328943.htm",
      "contextRef": "c20230103to20230103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "cmmb_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share [Member]"
       }
      }
     },
     "localname": "AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember",
     "nsuri": "http://chemomab.com/20230103",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_OrdinarySharesNoParValuePerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, no par value per share [Member]"
       }
      }
     },
     "localname": "OrdinarySharesNoParValuePerShareMember",
     "nsuri": "http://chemomab.com/20230103",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityListingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Listings [Line Items]"
       }
      }
     },
     "localname": "EntityListingsLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityListingsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container for exchange listing information for an entity",
        "label": "Entity Listings [Table]"
       }
      }
     },
     "localname": "EntityListingsTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://chemomab.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001178913-23-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-23-000010-xbrl.zip
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M7>ESV\:2_[Y5^S_,,O7>LVM)FJ=(2K+JV;(=^T5.5)9?MG:_#8 !.1& 068
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M[E:$>\(UY ZOA(=7IL&KPL.K+EUQ6,?#E03*1[#UJ 2H4IG!A1D1JBSR!S1
M?@YS96%21H)Q!H8%. W3)(0#<84#01L'<@\'>(,#L'!N2IB4P: !$!GIWU
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M9*9F)Z + %UA@9!U6,RU2&  6#V,!/'ERC*2AB8Q  [18[TV1J&&2:MQI%H
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M0YTG9I?>0[;>#S<001MZFNWF<<#L3NR7B2I5">M:EC22#'A__6:5)%NR)6S
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MYKLI^I;1[L**",5CYNE\=5&Q<WP/2!#8RMFCQ!+"*;J*F<NU>XK\$)UD*1J
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M']=XE&KQ]-1>CT1TPL-(O6$V"N#A/U!+ 0(4 Q0    ( *TX(U9$4S_:Z ,
M $<2   1              "  0    !C;6UB+3(P,C,P,3 S+GAS9%!+ 0(4
M Q0    ( *TX(U9VC!2"+@<  -M'   5              "  1<$  !C;6UB
M+3(P,C,P,3 S7V1E9BYX;6Q02P$"% ,4    " "M."-6\,)7"IP*  #S;P
M%0              @ %X"P  8VUM8BTR,#(S,#$P,U]L86(N>&UL4$L! A0#
M%     @ K3@C5AI9:>0Y!P  GU   !4              ( !1Q8  &-M;6(M
M,C R,S Q,#-?<')E+GAM;%!+ 0(4 Q0    ( *TX(U8,TB6T+!<  )!K   0
M              "  ;,=  !E>&AI8FET7SDY+3$N:'1M4$L! A0#%     @
MK3@C5HAGKQ-8%   1Y(   T              ( !#34  'IK,C,R.#DT,RYH
8=&U02P4&      8 !@"! 0  D$D

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
